Scott Myers

Scott Myers is the current President & CEO of Altria Group Distribution Company at Altria Group. Prior to this, they were with Dynavax Technologies, Qiming Venture Partners USA, and Trillium Therapeutics Inc. from April 2021 to November 2021, where they served as an Independent Director.

Trillium Therapeutics Inc. was acquired by Pfizer (PFE) in November of 2021. The company was formed in Ontario and named after the province’s official flower, Trillium grandiflorum. Trillium Therapeutics is an immuno-oncology company targeting CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a “don’t eat me” signal that blocks the ability of macrophages to phagocytose and destroy tumor cells. By blocking this “don’t eat me” signal with decoy receptors, they aim to unmask tumor cells and make them visible to the immune system. As a leading CD47-focused company, Trillium Therapeutics has two decoy receptors (TTI-621 and TTI-622) that are currently being evaluated in patients with hematological malignancies and solid tumors.

At the end of 2019, under new leadership, Trillium underwent a transformational program that included corporate reorganization, the creation of a more clinical development-centric organization and

Scott Myers has a MBA from The University of Chicago Booth School of Business in Finance and International Business. Scott also has a Bachelor of Arts - BA from Northwestern University in Biology/Biological Sciences, General. Lastly, they have a high school diploma from Springfield High School.

Scott Myers reports to Jody L. Begley, EVP & COO. Some of their coworkers include Michael Thorne-Begland - VP & Chief Inclusion, Diversity & Equity Officer, Kenya Blake - MD & GM, John Middleton Co., and Jennifer Hunter - SVP, Corporate Citizenship, Altria Client Services LLC.